Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for the treatment of serious immunological and inflammatory diseases, with an initial emphasis on IgA nephropathy (IgAN), a chronic and progressive autoimmune kidney disorder. The company operates within the biopharmaceutical and immunology industries and does not currently market approved products, deriving its value primarily from its clinical development pipeline.
The company’s lead and core asset is atacicept, a fusion protein designed to inhibit the B-cell survival factors BLyS and APRIL, which play a central role in antibody-mediated diseases. Vera Therapeutics positions itself as a pure-play IgAN-focused company, seeking to address an area of high unmet medical need with limited disease-modifying treatment options. Founded in 2016, the company evolved from early immunology research into a publicly traded biotechnology firm following its initial public offering in 2021, advancing atacicept through late-stage clinical development.
Business Operations
Vera Therapeutics’ operations are centered on a single operating segment: biopharmaceutical research and development, with activities spanning clinical trial execution, regulatory engagement, manufacturing oversight, and corporate administration. The company generates no product revenue and funds operations primarily through equity offerings and cash reserves disclosed in its SEC filings. Research and development expenses represent the majority of operating costs.
The company controls global development and commercialization rights to atacicept for IgAN through a licensing agreement with Merck KGaA, the original developer of the molecule. Vera does not own manufacturing facilities and relies on third-party contract manufacturers and clinical research organizations. Operations are primarily domestic, with international clinical trial sites supporting global regulatory ambitions.
Strategic Position & Investments
Strategically, Vera Therapeutics is focused on advancing atacicept as a potential first-line, disease-modifying therapy for IgAN, supported by positive Phase 2 data and ongoing Phase 3 clinical development. The company’s growth strategy is concentrated on achieving regulatory approval in major markets and preparing for potential commercialization, rather than portfolio diversification.
The most significant investment is the continued funding of late-stage clinical trials and manufacturing scale-up for atacicept. Vera has not completed multiple acquisitions or built a broad subsidiary portfolio, reflecting a disciplined, asset-focused strategy common among late-stage clinical biotechnology companies. Its exposure to emerging sectors is concentrated in autoimmune and B-cell–mediated diseases, with potential optionality for lifecycle expansion into related indications if clinical and regulatory outcomes support it.
Geographic Footprint
Vera Therapeutics is headquartered in the United States, with its principal executive offices in South San Francisco, California, a major biotechnology hub. Corporate operations, research oversight, and executive management are based domestically.
While the company does not maintain extensive international offices, its clinical development program has a global footprint, including trial sites across North America, Europe, and parts of Asia-Pacific. This international presence is driven by regulatory requirements for late-stage trials and the global prevalence of IgAN, positioning the company for potential future commercialization in multiple regions.
Leadership & Governance
Vera Therapeutics is led by an executive team with experience in biotechnology development, immunology, and commercial strategy. The leadership emphasizes scientific rigor, disciplined capital allocation, and a focused clinical execution model aimed at delivering a single high-impact therapy to market.
Key executives include:
- Marshall Fordyce – President and Chief Executive Officer
- Jayson Dallas – Chief Financial Officer
- Harold Carter – Chief Medical Officer
- Paul Bolno – Chief Operating Officer
- Steven Deitcher – Chief Development Officer
The company is governed by a board of directors with backgrounds in biopharmaceutical leadership, clinical development, and capital markets, aligning governance oversight with the company’s late-stage development and pre-commercial objectives.